KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
Paul Chew, MD
Advertisement
Articles by Paul Chew, MD
A discussion of the cost and time put into clinical trials.
Advertisement
Latest Updated Articles
Clinical Trials Don't Have to Cost Too Much or Take Too LongPublished: May 8th 2018 | Updated:
- KOLs: An Endangered Buzzword
Published: March 20th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release
2
FDA Approves GSK's Exdensur as Twice-Yearly Add-On Therapy for Severe Asthma
3
Four Republicans Break with House GOP to Force Vote on Extending ACA Tax Credits
4
Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience
5